$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000114420414013289 Filed on March 04, 2014

Income Statement

Concept	2012 Q4	2012	2011 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$660.0K	$2.040M
YoY Change		1175.0%
% of Gross Profit
Research & Development		$1.501M
YoY Change		1776.58%
% of Gross Profit
Depreciation & Amortization	$10.00K	$24.32K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.590M	$1.501M
YoY Change		552.72%
Operating Profit		-$3.974M
YoY Change
Interest Expense	$300.0K	-$1.710M
YoY Change		-17200.0%
% of Operating Profit
Other Income/Expense, Net	$100.0K	-$1.712M
YoY Change		970.1%
Pretax Income	-$1.190M	$2.988M
YoY Change		-866.08%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$1.190M	-$5.687M
YoY Change		1358.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$119.0M	-$569.0M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.300M	$1.250M	$900.0K
YoY Change	44.44%	35.87%
Cash & Equivalents	$1.230M	$1.230M	$908.8K
Short-Term Investments	$0.00	$20.00K	$0.00
Other Short-Term Assets	$71.43K	$410.0K	$0.00
YoY Change		4000.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.667M	$1.670M	$900.0K
YoY Change	85.17%	79.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$617.4K	$620.0K	$0.00
YoY Change		3000.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$30.00K	$0.00
YoY Change		50.0%
Total Long-Term Assets	$648.9K	$650.0K	$100.0K
YoY Change	548.91%	1200.0%
TOTAL ASSETS
Total Short-Term Assets	$1.667M	$1.670M	$900.0K
Total Long-Term Assets	$648.9K	$650.0K	$100.0K
Total Assets	$2.315M	$2.320M	$1.000M
YoY Change	131.55%	136.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$300.0K	$250.0K	$0.00
YoY Change		733.33%
Accrued Expenses	$232.3K	$320.0K	$100.0K
YoY Change	132.33%	255.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$566.8K	$570.0K	$100.0K
YoY Change	466.76%	375.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.800M	$2.820M	$700.0K
YoY Change	300.0%	327.27%
Total Long-Term Liabilities	$2.800M	$2.820M	$700.0K
YoY Change	300.0%	327.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$566.8K	$570.0K	$100.0K
Total Long-Term Liabilities	$2.800M	$2.820M	$700.0K
Total Liabilities	$3.400M	$3.380M	$800.0K
YoY Change	325.0%	327.85%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$1.454K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.070M	-$1.070M	$193.0K
YoY Change
Total Liabilities & Shareholders Equity	$2.315M	$2.320M	$1.000M
YoY Change	131.55%	136.73%

Cashflow Statement

Concept	2012 Q4	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$1.190M	-$5.687M
YoY Change		1358.21%
Depreciation, Depletion And Amortization	$10.00K	$24.32K	$0.00
YoY Change
Cash From Operating Activities	-$1.460M	-$2.980M	-$140.0K
YoY Change	942.86%	2028.57%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	$534.6K	-$20.00K
YoY Change	2400.0%	-2773.17%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	-$30.00K	-$30.00K
YoY Change	-66.67%	0.0%
Cash From Investing Activities	-$510.0K	-$560.0K	-$60.00K
YoY Change	750.0%	833.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.390M	3.870M	1.100M
YoY Change	117.27%	251.82%
NET CHANGE
Cash From Operating Activities	-1.460M	-2.980M	-140.0K
Cash From Investing Activities	-510.0K	-560.0K	-60.00K
Cash From Financing Activities	2.390M	3.870M	1.100M
Net Change In Cash	420.0K	330.0K	900.0K
YoY Change	-53.33%	-63.33%
FREE CASH FLOW
Cash From Operating Activities	-$1.460M	-$2.980M	-$140.0K
Capital Expenditures	-$500.0K	$534.6K	-$20.00K
Free Cash Flow	-$960.0K	-$3.515M	-$120.0K
YoY Change	700.0%	2828.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7599723	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q1	drio	Stock Registered During Period Shares Initial Registration StockRegisteredDuringPeriodSharesInitialRegistration	9430162	shares
CY2013Q3	drio	Stock Registered During Period Shares Second Registration StockRegisteredDuringPeriodSharesSecondRegistration	7936690	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1230034	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-86381	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4115814	USD
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2263395	USD
CY2012Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	13422	USD
CY2013Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	38034	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	21566	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	153600	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	401522	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	474818	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	1666544	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	2929847	USD
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	31545	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	41167	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	617364	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1144800	USD
CY2012Q4	us-gaap	Assets Assets	2315453	USD
CY2013Q4	us-gaap	Assets Assets	4115814	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	250352	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	586330	USD
CY2012Q4	drio	Other Accounts Payable And Accrued Expenses OtherAccountsPayableAndAccruedExpenses	316403	USD
CY2013Q4	drio	Other Accounts Payable And Accrued Expenses OtherAccountsPayableAndAccruedExpenses	919814	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	566755	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1506144	USD
CY2012Q4	drio	Liability Related To Warrants LiabilityRelatedToWarrants	2817741	USD
CY2013Q4	drio	Liability Related To Warrants LiabilityRelatedToWarrants	2696051	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1454	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	2006	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5001425	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19915313	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	6071922	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	20003700	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-1069043	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2315453	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	564143	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3213270	USD
CY2013	drio	Unvested Shares Of Common Stock At Four Monthly Issuances UnvestedSharesOfCommonStockAtFourMonthlyIssuances	41667	shares
CY2012	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1107852	USD
CY2013Q1	drio	Share Based Compensation Arrangement By Share Based Payment Award Options To Nonemployee Director Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToNonemployeeDirectorGrantsInPeriod	600000	shares
CY2013Q1	drio	Share Based Compensation Arrangements By Share Based Payment Award Options Grants To Nonemployee Director In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsToNonemployeeDirectorInPeriodWeightedAverageExercisePrice	1.50
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2013-03-31
CY2012	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1038998	USD
CY2013	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1553680	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2710719	USD
CY2012	drio	Legal And Professional Fees LegalAndProfessionalFees	310256	USD
CY2013	drio	Legal And Professional Fees LegalAndProfessionalFees	1342073	USD
	drio	Legal And Professional Fees LegalAndProfessionalFees	1691106	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	390403	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	2388415	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2778818	USD
CY2012	drio	Stock And Warrants Issued During Period To Service Provider StockAndWarrantsIssuedDuringPeriodToServiceProvider	437499	USD
CY2013	drio	Stock And Warrants Issued During Period To Service Provider StockAndWarrantsIssuedDuringPeriodToServiceProvider	1011370	USD
	drio	Stock And Warrants Issued During Period To Service Provider StockAndWarrantsIssuedDuringPeriodToServiceProvider	1448869	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14547689	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20071816	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14547689	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20071816	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	603411	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2982680	USD
CY2012	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19851	USD
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1501265	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4912457	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6491617	USD
CY2012	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	295987	USD
CY2013	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2354403	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2650390	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2177156	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6295538	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8629512	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-3974408	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-13562398	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17771519	USD
CY2012	drio	Revaluation Of Warrant Income Expenses RevaluationOfWarrantIncomeExpenses	-1606378	USD
CY2013	drio	Revaluation Of Warrant Income Expenses RevaluationOfWarrantIncomeExpenses	-293542	USD
	drio	Revaluation Of Warrant Income Expenses RevaluationOfWarrantIncomeExpenses	-1884053	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105787	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75838	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-348128	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1712165	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-369380	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2232181	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-5686573	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-13931778	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20003700	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.46
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.76
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12375002	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18313073	shares
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	0	USD
	drio	Stock Issued During Period Value Issued For Services2 StockIssuedDuringPeriodValueIssuedForServices2	650	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000	USD
	drio	Stock Issued During Period Value Issued For Services1 StockIssuedDuringPeriodValueIssuedForServices1	100	USD
	drio	Stock Issued During Period Value New Issues October And November2011 StockIssuedDuringPeriodValueNewIssuesOctoberAndNovember2011	481490	USD
	drio	Stock Issued During Period Value New Issues December2011 StockIssuedDuringPeriodValueNewIssuesDecember2011	86253	USD
CY2012	drio	Stock Issued During Period Value New Issues February And March2012 StockIssuedDuringPeriodValueNewIssuesFebruaryAndMarch2012	540109	USD
CY2012	drio	Stock And Warrant Issued During Period Value New Issues August2012 StockAndWarrantIssuedDuringPeriodValueNewIssuesAugust2012	498157	USD
CY2012	drio	Stock Issued During Period Value New Issues September And October2012 StockIssuedDuringPeriodValueNewIssuesSeptemberAndOctober2012	2384478	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	437499	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	487870	USD
CY2013	drio	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	707853	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	564143	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3213270	USD
	us-gaap	Net Income Loss NetIncomeLoss	-385349	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	193144	USD
CY2012	drio	Stockbased Compensation Warrants And Restricted Shares StockbasedCompensationWarrantsAndRestrictedShares	1001642	USD
CY2013	drio	Stockbased Compensation Warrants And Restricted Shares StockbasedCompensationWarrantsAndRestrictedShares	4224640	USD
	drio	Stockbased Compensation Warrants And Restricted Shares StockbasedCompensationWarrantsAndRestrictedShares	5226282	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	101263	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	258110	USD
CY2012	us-gaap	Depreciation Depreciation	24317	USD
CY2013	us-gaap	Depreciation Depreciation	839249	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-564531	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1641454	USD
CY2012	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3868480	USD
CY2013	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9981932	USD
CY2013	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	292606	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	292606	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3868480	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	919815	USD
CY2012	drio	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-1606378	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	271458	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	521810	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	12762	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	13843	USD
	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	122304	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2042558	USD
	us-gaap	Depreciation Depreciation	864070	USD
CY2012	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	391747	USD
CY2013	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	-1547	USD
	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	402559	USD
CY2012	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	228090	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10274538	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15244895	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	321269	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1033361	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2263395	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	908765	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	64520	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	64520	USD
CY2013	drio	Conversionofwarantliabilitytocommonstock Conversionofwarantliabilitytocommonstock	415232	USD
	drio	Conversionofwarantliabilitytocommonstock Conversionofwarantliabilitytocommonstock	415232	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	133950	USD
CY2013	drio	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-293542	USD
	drio	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-1884053	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10633911	USD
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	162622	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	195910	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	26605	USD
CY2012	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	9386	USD
CY2013	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	92302	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	534634	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1400373	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	13422	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	13422	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2347589	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	14952289	USD
CY2012	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	83824	USD
CY2012	drio	Conversionofwarantliabilitytocommonstock Conversionofwarantliabilitytocommonstock	0	USD
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Trading Symbol TradingSymbol	DRIO
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22626879	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	LabStyle Innovations Corp.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001533998
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	51420261	USD
CY2013	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	98208	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	98208	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	84076	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	328743	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	232327	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591071	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0037	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0033	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0096	pure
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	239087	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	204718	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	150245	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	594050	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0298	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	51482	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	120685	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	642185	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 56.699pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> </td> <td style="WIDTH: 28.35pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>a.</font></font></div> </td> <td style="TEXT-ALIGN: justify; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif">Use of estimates:</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; TEXT-INDENT: -56.7pt; MARGIN: 0in 0in 0pt 56.7pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif">  </font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1102400	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4043340	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 56.699pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> </td> <td style="WIDTH: 28.35pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"> j.</font></font></div> </td> <td style="TEXT-ALIGN: justify; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"> Concentrations of credit risk:</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; MARGIN: 0in 0in 0pt" align="justify"><font style="LINE-HEIGHT: 110%; FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">  </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and other accounts receivable and prepaid expenses.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">  </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: 110%; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">The majority of cash and cash equivalents of the Company and Ltd. are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents may be in excess of insured limits and are not insured in other jurisdictions.</font></font> <font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY:times new roman,times,serif">Generally, cash and cash equivalents may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1102400	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4043340	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2987718	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	4340178	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7587853	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2698855	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	20003700	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.265	pure
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3062627	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	468073	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012	drio	Warrants Expiration Period WarrantsExpirationPeriod	P3Y
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5686573	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13931778	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20003700	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8245312	shares
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	9591600	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	12415847	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5686573	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	13931778	USD
CY2012Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	330092	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	423336	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	71430	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4556544	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10858566	shares
CY2013	drio	Percentage Of Monthly Deposits Behalf Of Insurance Companies PercentageOfMonthlyDepositsBehalfOfInsuranceCompanies	0.0833	pure
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	854678	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3101245	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	247722	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	942095	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1969701	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24821	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824901	USD
CY2013	drio	Stock Issued During Period Value New Issues February And June2013 StockIssuedDuringPeriodValueNewIssuesFebruaryAndJune2013	996422	USD
CY2013	drio	Warrant Issued During Period For Services Value March And May2013 WarrantIssuedDuringPeriodForServicesValueMarchAndMay2013	523500	USD
CY2013	drio	Stock Issued During Period Value New Issues April And May2013 StockIssuedDuringPeriodValueNewIssuesAprilAndMay2013	8985510	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.52
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.44
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1152241	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P6M7D
CY2012	drio	Stock Options Exercise Price Per Share StockOptionsExercisePricePerShare	1.00
CY2012	drio	Amended Stock Options Exercise Price Per Share AmendedStockOptionsExercisePricePerShare	0.52
CY2012	us-gaap	Advertising Expense AdvertisingExpense	158039	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	175231	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0.62	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0.74	USD
CY2013	drio	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants	292591	shares
CY2013	drio	Stock Issued During Period Shares Cashless Exercise StockIssuedDuringPeriodSharesCashlessExercise	62835	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2100000	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.25	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3013250	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	15000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	369500	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4728750	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3394500	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3410750	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.32
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.13
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.53
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.12
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.13
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y25D
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1.18	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0.74	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.499	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5863	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.751	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7577	pure
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD

Files In Submission

Name	View Source	Status
0001144204-14-013289-index-headers.html	Edgar Link	pending
0001144204-14-013289-index.html	Edgar Link	pending
0001144204-14-013289.txt	Edgar Link	pending
0001144204-14-013289-xbrl.zip	Edgar Link	pending
drio-20131231.xml	Edgar Link	completed
drio-20131231.xsd	Edgar Link	pending
drio-20131231_cal.xml	Edgar Link	unprocessable
drio-20131231_def.xml	Edgar Link	unprocessable
drio-20131231_lab.xml	Edgar Link	unprocessable
drio-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ft0001img-1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v368531_10k.htm	Edgar Link	pending
v368531_ex21-1.htm	Edgar Link	pending
v368531_ex31-1.htm	Edgar Link	pending
v368531_ex31-2.htm	Edgar Link	pending
v368531_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2012 Q4 Form 10-K Financial Statement

#000114420414013289 Filed on March 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2012 Q4 Form 10-K Financial Statement

#000114420414013289 Filed on March 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio